Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Bosutinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC known ✓ | P12931 | 19/20 | 1.00 |
| ▸ | ABL1 known ✓ | P00519 | 5/20 | 1.00 |
| ▸ | BCR known ✓ | P11274 | 4/20 | 1.00 |
| ▸ | LYN known ✓ | P07948 | 1/20 | 1.00 |
| ▸ | HCK known ✓ | P08631 | 1/20 | 1.00 |
| ▸ | FYN | P06241 | 2/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 2/20 | 1.00 |
| ▸ | ABL2 | P42684 | 2/20 | 1.00 |
| ▸ | WEE2 | P0C1S8 | 2/20 | 1.00 |
| ▸ | WEE1 | P30291 | 2/20 | 1.00 |
| ▸ | PKMYT1 | Q99640 | 2/20 | 1.00 |
| ▸ | STK25 | O00506 | 1/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | RIOK3 | O14730 | 1/20 | 1.00 |
| ▸ | MAP2K7 | O14733 | 1/20 | 1.00 |
| ▸ | CHEK1 | O14757 | 1/20 | 1.00 |
| ▸ | CASK | O14936 | 1/20 | 1.00 |
| ▸ | GAK | O14976 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | MAP3K13 | O43283 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosutinib SCHEMBL19207253 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL2887945 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29389315 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29428159 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL29350234 | 1.00 | SRC (1.00) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207270 | 0.98 | SRC (0.97) | SRCABL1BCRFYNKCNH2 | |
| Bosutinib SCHEMBL19207277 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL676669 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453343 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 | |
| SCHEMBL30453317 | 0.96 | SRC (0.92) | SRCABL1BCRFYNKCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1082 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250312349-A1 | COMPOSITION AND METHODS OF TREATING INTRACELLULAR PATHOGEN INFECTION | UNIV HOSPITALS CLEVELAND MEDICAL CENTER (US) | 2025-10-09 | — | — | US | claimed |
| US-20240398799-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2024-12-05 | — | — | US | claimed |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | BERGENBIO ASA (NO) | 2023-08-10 | — | — | US | claimed |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | BERGENBIO ASA (NO) | 2023-05-18 | — | — | US | claimed |
| US-20230149415-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-05-18 | — | — | US | claimed |
| CN-116075303-A | Method of selecting patients treated with a combination of an AXL inhibitor and an immune checkpoint modulator | 卑尔根生物股份公司 | 2023-05-05 | — | — | CN | claimed |
| CN-115916344-A | AXL inhibitors for antiviral therapy | 卑尔根生物股份公司 | 2023-04-04 | — | — | CN | claimed |
| US-20230078425-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-03-16 | — | — | US | claimed |
| US-20230073494-A1 | COMPOSITIONS AND METHODS FOR GENERATING SYNTHETIC LETHALITY IN TUMORS | ENGINE BIOSCIENCES PTE. LTD. (SG) | 2023-03-09 | — | — | US | claimed |
| EP-4138823-A1 | METHOD OF SELECTING PATIENTS FOR TREATMENT WITH A COMBINATION OF AN AXL INHIBITOR AND AN IMMUNE CHECKPOINT MODULATOR | BerGenBio ASA (NO) | 2023-03-01 | — | — | EP | claimed |
| EP-1499594-B1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH CORP (US) | 2005-08-17 | — | — | EP | claimed |
| WO-2005065074-A2 | PROTECTION OF TISSUES AND CELLS FROM CYTOTOXIC EFFECTS OF IONIZING RADIATION BY ABL INHIBITORS | TEMPLE UNIVERSITY OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2005-07-21 | — | — | WO | claimed |
| WO-2005046693-A1 | 4-ANILINO-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF CHRONIC MYELOGENOUS LEUKEMIA (CML) | WYETH (US) | 2005-05-26 | — | — | WO | claimed |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | WYETH (US) | 2005-05-12 | — | — | US | claimed |
| EP-1499594-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | Wyeth Holdings Corporation (US) | 2005-01-26 | — | — | EP | claimed |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | WYETH | 2004-11-18 | — | — | US | claimed |
| WO-2004075898-A1 | 4-[(2,4-DICHLORO-5-METHOXYPHENYL)AMINO]-6-ALKOXY-3-QUINOLINECARBONITRILES FOR THE TREATMENT OF ISCHEMIC INJURY | WYETH (US) | 2004-09-10 | — | — | WO | claimed |
| US-6780996-B2 | KINASE INHIBITORS; ANTICANCER AGENTS | WYETH HOLDINGS CORPORATION | 2004-08-24 | — | — | US | claimed |
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | WYETH HOLDINGS CORPORATION | 2003-11-13 | — | — | US | claimed |
| WO-2003093241-A1 | PROCESS FOR THE PREPARATION OF 7-SUBSTITUTED-3-QUINOLINE AND 3-QUINOL-4-ONE CARBONITRILES | WYETH HOLDINGS CORPORATION (US) | 2003-11-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212276-A1 | Process for the preparation of 7-substituted-3 quinolinecarbonitriles | MAP4K2, MAP3K7, MAP4K1 | SRC 386/4885ABL1 26/4885BCR 1123/4885 |
| US-20230250169-A1 | AXL Inhibitors for Antiviral Therapy | FLT3, AXL, SARS1 | SRC 35/4885ABL1 22/4885BCR 2953/4885 |
| US-20040229880-A1 | 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-alkoxy-3-quinolinecarbonitriles for the treatment of ischemic injury | TNNI3, TXN2, AIFM1 | SRC 4373/4885ABL1 655/4885BCR 3690/4885 |
| US-20050101780-A1 | 4-anilino-3-quinolinecarbonitriles for the treatment of chronic myelogenous leukemia (CML) | ABL1, MCL1, NPM1 | SRC 244/4885ABL1 1/4885BCR 4/4885 |
| US-20230151100-A1 | Method of Selecting Patients for Treatment with a Combination of an AXL Inhibitor and an Immune Checkpoint Modulator | STK11, MERTK, AXL | SRC 118/4885ABL1 346/4885BCR 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.